We are striving to build the preeminent company developing gene editing medicines to treat patients with cardiovascular disease, leveraging the expertise and capabilities of our team whose singular focus is on addressing the root causes of the world’s most common cause of death. Our goal is to disrupt today’s chronic care model for treating cardiovascular disease by providing a new therapeutic approach with single-course gene editing treatments.
Verve brings together multiple breakthroughs in 21st century biomedicine — human genetic analysis, gene editing, messenger RNA (mRNA) -based therapies and lipid nanoparticle (LNP) delivery — to realize a new future of longevity and vitality for tens of millions of people around the globe with or at risk for cardiovascular disease.
Verve has been purpose-built for the task ahead, with a team of world-leading experts in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development and commercialization.
Scientific Advisory Board
Collaborations and Licensing
Verve has assembled a portfolio of gene editing and delivery technologies through strategic collaborations and licensing agreements with industry leaders, including Beam Therapeutics, the Broad Institute, Harvard University and Acuitas Therapeutics, Inc.